A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen

• Status: Completed
• Trial end date: 2017-02-01

Summary

A prospective, multicenter, open, randomized Phase 2a trial to confirm a sustained virological suppression defined as HIV-RNA <50 copies/ml of 3 different doses of Fozivudine in context to a standard Zidovudine based antiretroviral therapy regimen after 24 weeks of treatment in ART naïve, non subtype B HIV-1 infected individuals from Tanzania and Ivory Coast.

• Phase: Phase 2

Details

• Lead Sponsor: Michael Hoelscher
• Collaborators: ANRS, Emerging Infectious Diseases; Bernhard Nocht Institute for Tropical Medicine; European and Developing Countries Clinical Trials Partnership (EDCTP); French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; Kumasi Centre for Collaborative Research (KCCR); National Institute for Medical Research, Tanzania; Pharmaceutical Company (Chiracon GmbH); Pharmaceutical Company (STADA Vietnam Joint Venture Co. Ltd.); Treichville Academic hospital center, Division of infectious and tropical diseases (SMIT)
• Treatments: Efavirenz; Lamivudine; Zidovudine